UNIT 10.13 The Fentanyl/Etomidate-Anesthetized Beagle (FEAB) Model in Safety Pharmacology Assessment

  1. Henk J. van der Linde,
  2. Bruno Van Deuren,
  3. Yves Somers,
  4. Ard Teisman,
  5. David J. Gallacher

Published Online: 1 SEP 2011

DOI: 10.1002/0471141755.ph1013s54

Current Protocols in Pharmacology

Current Protocols in Pharmacology

How to Cite

van der Linde, H. J., Deuren, B. V., Somers, Y., Teisman, A. and Gallacher, D. J. 2011. The Fentanyl/Etomidate-Anesthetized Beagle (FEAB) Model in Safety Pharmacology Assessment. Current Protocols in Pharmacology. 54:10.13:10.13.1–10.13.21.

Author Information

  1. Center of Excellence for Cardiovascular Safety Research & Mechanistic Pharmacology, Janssen Pharmaceutical Research & Development, A Division of Janssen Pharmaceutica NV, Pharmaceutical Companies of Johnson & Johnson, Beerse, Belgium

Publication History

  1. Published Online: 1 SEP 2011
  2. Published Print: SEP 2011


This unit describes a procedure for performing safety studies in the anesthetized beagle dog. Detailed are the anesthetic regime, the surgical procedure, and all materials needed to perform cardiovascular, central nervous system, and respiratory safety studies in these animals. An overview of all parameters that can be measured and calculated is provided, as are experimental protocols. Endpoints discussed include hemodynamic, electrocardiological, respiratory, arterial blood, and electroencephalogical parameters. Also presented are a formula to correct QT interval for changes in core body temperature and an overview of changes in ECG, MAP, and EEG traces that may occur during safety studies. The information provided yields a multiparametric model for performing reliable safety studies in anesthetized dogs. Curr. Protoc. Pharmacol. 54:10.13.1-10.13.21. © 2011 by John Wiley & Sons, Inc.


  • model;
  • dog;
  • anesthesia;
  • safety pharmacology;
  • fentanyl;
  • etomidate;
  • cardiovascular;
  • respiratory;
  • CNS